Results 131 to 140 of about 1,716,393 (201)

Application of MPBT Assay for Multiplex Determination of Infectious Titers and for Selection of the Optimal Formulation for the Trivalent Novel Oral Poliovirus Vaccine. [PDF]

Viruses
Manukyan H, Lal M, Zhu C, Singh O, Lin TL, Tritama E, Chumakov K, Lee SM, Laassri M.   +8 more
europepmc   +1 more source

Sequential inactivated and oral poliovirus vaccine schedules: a balancing act. [PDF]

Lancet Infect Dis, 2020
Zaman K, Anand A.
europepmc   +1 more source

Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. [PDF]

Risk Anal, 2021
Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM.   +9 more
europepmc   +1 more source

Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. [PDF]

Risk Anal
Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM.   +6 more
europepmc   +1 more source

Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2. [PDF]

Vaccines (Basel), 2021
Manukyan H, Tritama E, Wahid R, Ansari A, Konz J, Chumakov K, Laassri M.   +6 more
europepmc   +1 more source

Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial. [PDF]

Vaccine
Snider CJ, Zaman K, Estivariz CF, Aziz AB, Yunus M, Haque W, Hendley WS, Weldon WC, Oberste MS, Pallansch MA, Wassilak SGF, Anand A.   +11 more
europepmc   +1 more source

[Vaccine-associated poliomyelitis: safety of the oral poliovirus vaccine, Brazil, 2013-2023Poliomielitis asociada a poliovirus derivados de la vacuna: seguridad de la vacuna oral contra la poliomielitis en Brasil, 2013-2023]. [PDF]

Rev Panam Salud Publica
Silva RMA, Kobayashi CD, Martins AF, Porto VBG, Araujo ACM, Andrade PHS, da Nóbrega MEB, Cabral CM, de Moraes MB, Ikeda do Carmo GM, Cardoso FD, de Siqueira GA, de Matos ZM, Percio J, Fernandes EG.   +14 more
europepmc   +1 more source

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.

Lancet Microbe
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, Sáez-Llorens X, Rüttimann RW, Van Damme P, De Coster I, Wright PF.   +14 more
europepmc   +1 more source

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. [PDF]

Lancet Infect Dis
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, Rüttimann R.   +11 more
europepmc   +1 more source

The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks.

Cell Host Microbe, 2021
Valesano AL, Taniuchi M, Fitzsimmons WJ, Islam MO, Ahmed T, Zaman K, Haque R, Wong W, Famulare M, Lauring AS.   +9 more
europepmc   +1 more source